Reading UTMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UTMD free→Reading UTMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UTMD free→QuarterlyIQ Insights · UTMD
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(2.1) + peer(0.2*5.5) + term(0.0) → 1.86% (capped ±15.0)
in 36 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2026 and forward-looking statements relating to 2026 and beyond as presented in a press release dated April 23, 2026. The information in this report (including Exhibit 99.1) is being furnished pursuant to
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated January 29, 2026. The information in this report (including Exhibit 99.1) is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated October 23, 2025. The information in this report (including Exhibit 99.1) is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated July 24, 2025. The information in this report (including Exhibit 99.1) is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated April 29, 2025. The information in this report (including Exhibit 99.1) is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2024 and forward-looking statements relating to 2024 and beyond as presented in a press release dated January 28, 2025. The information in this report (including Exhibit 99.1) is being furnished pursuant to